Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01281306 · ClinicalTrials.gov registry record · Phase 2
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 910
- Enrollment target
NCT01281306 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 910 participants.
The verdict
NCT01281306, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 910 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate dose response of blood pressure lowering for 4 doses of AHU377, given once daily (50 mg, 100 mg, 200 mg and 400 mg) in combination with a fixed dose of valsartan (320 mg).
Interventions
- DRUG Placebo
- DRUG Valsartan
- DRUG LCZ696
- DRUG AHU377
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 910 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01281306
The ClinicalTrials.gov registry entry for NCT01281306 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 910 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01281306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01281306 about?
NCT01281306 is a clinical study titled "An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension". The purpose of the study is to evaluate dose response of blood pressure lowering for 4 doses of AHU377, given once daily (50 mg, 100 mg, 200 mg and 400 mg) in combination with a fixed dose of valsartan (320 mg).
What is the current status of trial NCT01281306?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 910 participants. The study started on 2011-01. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01281306?
The interventions under investigation include: Placebo (DRUG), Valsartan (DRUG), LCZ696 (DRUG), AHU377 (DRUG).
Who is sponsoring clinical trial NCT01281306?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.